{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:57:35Z","timestamp":1794265055573,"version":"4.9.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007408","name":"Medical Center, University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013678","name":"Cancer Center, University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1 CA233330"],"award-info":[{"award-number":["UG1 CA233330"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 - 5R01CA255780"],"award-info":[{"award-number":["R01 - 5R01CA255780"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019775","name":"Moores Cancer Center, UC San Diego Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011539","name":"Masonic Cancer Center, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030675","name":"Loyola Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015190","name":"Houston Methodist Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009819","name":"Chao Family Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006733","name":"Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ygyno.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:35:21Z","timestamp":1742225721000},"page":"122-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial"],"prefix":"10.1016","volume":"195","author":[{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren K.","family":"Mell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanthi S.","family":"Lea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha R.","family":"Amarnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Javier","family":"Santos-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Mayadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Jegadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad A.","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo P.","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Feddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"MacKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.007_bb0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.6004\/jnccn.2021.0038","article-title":"NCCN guidelines(R) insights: uterine neoplasms, version 3.2021","volume":"19","author":"Abu-Rustum","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"35","key":"10.1016\/j.ygyno.2025.03.007_bb0015","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis C","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2025.03.007_bb0020","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1200\/JCO.2006.09.4532","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a gynecologic oncology group study","volume":"25","author":"Rose","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.007_bb0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","article-title":"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a gynecologic oncology group study","volume":"32","author":"DiSilvestro","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ijgc-00009577-200601000-00048","article-title":"Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a southwest oncology group study","volume":"16","author":"Smith","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.007_bb0035","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/ijgc-00009577-200605000-00033","article-title":"Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer","volume":"16","author":"Maluf","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.007_bb0040","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.03.007_bb0045","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Duenas-Gonzalez","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.03.007_bb0050","first-page":"2245","article-title":"Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells","volume":"58","author":"Kuo","year":"1998","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2025.03.007_bb0055","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ygyno.2025.03.007_bb0060","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0024-3205(81)90746-3","article-title":"Role of ribonucleotide reductase in expression in the neoplastic program","volume":"28","author":"Takeda","year":"1981","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.ygyno.2025.03.007_bb0065","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0006-2952(99)00419-0","article-title":"Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity","volume":"59","author":"Finch","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.007_bb0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2018.00149","article-title":"Triapine radiochemotherapy in advanced stage cervical cancer","volume":"8","author":"Kunos","year":"2018","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.007_bb0085","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijrobp.2009.10.075","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer","volume":"79","author":"Lim","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.ygyno.2025.03.007_bb0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijrobp.2016.11.027","article-title":"Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2)","volume":"97","author":"Mell","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2016.10.005","article-title":"Highly efficient training, refinement, and validation of a knowledge-based planning quality-control system for radiation therapy clinical trials","volume":"97","author":"Li","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.ygyno.2025.03.007_bb0100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semradonc.2020.05.009","article-title":"Knowledge-based planning for intact cervical cancer","volume":"30","author":"Yusufaly","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2021.08.019","article-title":"Positron emission tomography-guided bone marrow-sparing radiation therapy for locoregionally advanced cervix cancer: final results from the INTERTECC phase II\/III trial","volume":"112","author":"Williamson","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.007_bb0110","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.ijrobp.2020.06.071","article-title":"A multi-atlas approach for active bone marrow sparing radiation therapy: implementation in the NRG-GY006 trial","volume":"108","author":"Yusufaly","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.007_bb0115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IGC.0b013e31821dc8b5","article-title":"18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response","volume":"21","author":"Kunos","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10462","key":"10.1016\/j.ygyno.2025.03.007_bb0120","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"issue":"10434","key":"10.1016\/j.ygyno.2025.03.007_bb0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.007_bb0130","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.03.007_bb0135","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S1470-2045(23)00532-6","article-title":"The challenge of improving outcomes in locally advanced cervical cancer","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10434","key":"10.1016\/j.ygyno.2025.03.007_bb0140","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0140-6736(24)00468-9","article-title":"Immunotherapy plus chemoradiotherapy in cervical cancer management","volume":"403","author":"Tewari","year":"2024","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.ygyno.2025.03.007_bb0145","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.007_bb0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13014-018-1126-7","article-title":"Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis","volume":"13","author":"Lin","year":"2018","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.007_bb0155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.radonc.2021.10.015","article-title":"Pelvic bone marrow sparing radiotherapy for cervical cancer: a systematic review and meta-analysis","volume":"165","author":"Zhou","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.03.007_bb0160","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group","volume":"35","author":"Young","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.ygyno.2025.03.007_bb0165","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/jama.298.19.2289","article-title":"Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma","volume":"298","author":"Schwarz","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ygyno.2025.03.007_bb0170","first-page":"1059","article-title":"Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials","volume":"47","author":"Shankar","year":"2006","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2025.03.007_bb0175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"Potter","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:29:43Z","timestamp":1778664583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"alternative-id":["S0090825825000769"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}